These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

366 related items for PubMed ID: 15939920

  • 1. Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95).
    Lehmann J, Retz M, Wiemers C, Beck J, Thüroff J, Weining C, Albers P, Frohneberg D, Becker T, Funke PJ, Walz P, Langbein S, Reiher F, Schiller M, Miller K, Roth S, Kälble T, Sternberg D, Wellek S, Stöckle M, AUO-AB 05/95.
    J Clin Oncol; 2005 Aug 01; 23(22):4963-74. PubMed ID: 15939920
    [Abstract] [Full Text] [Related]

  • 2. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience.
    Stöckle M, Meyenburg W, Wellek S, Voges GE, Rossmann M, Gertenbach U, Thüroff JW, Huber C, Hohenfellner R.
    J Urol; 1995 Jan 01; 153(1):47-52. PubMed ID: 7966789
    [Abstract] [Full Text] [Related]

  • 3. Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer.
    Lehmann J, Franzaring L, Thüroff J, Wellek S, Stöckle M.
    BJU Int; 2006 Jan 01; 97(1):42-7. PubMed ID: 16336326
    [Abstract] [Full Text] [Related]

  • 4. Does HER2 immunoreactivity provide prognostic information in locally advanced urothelial carcinoma patients receiving adjuvant M-VEC chemotherapy?
    Tsai YS, Tzai TS, Chow NH.
    Urol Int; 2007 Jan 01; 79(3):210-6. PubMed ID: 17940352
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer.
    Freiha F, Reese J, Torti FM.
    J Urol; 1996 Feb 01; 155(2):495-9; discussion 499-500. PubMed ID: 8558644
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
    George L, Bladou F, Bardou VJ, Gravis G, Tallet A, Alzieu C, Serment G, Salem N.
    Urology; 2004 Sep 01; 64(3):488-93. PubMed ID: 15351577
    [Abstract] [Full Text] [Related]

  • 10. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline.
    Segal R, Winquist E, Lukka H, Chin JL, Brundage M, Markman BR, Cancer Care Ontario Practice Guidelines Initiative Genitourinary Cancer Disease Site Group.
    Can J Urol; 2002 Oct 01; 9(5):1625-33. PubMed ID: 12431323
    [Abstract] [Full Text] [Related]

  • 11. [Neoadjuvant and adjuvant chemotherapy of bladder cancer].
    Kuroda M, Kotake T.
    Gan To Kagaku Ryoho; 1994 Oct 01; 21 Suppl 3():362-9. PubMed ID: 7986116
    [Abstract] [Full Text] [Related]

  • 12. Phase I-II pilot study on the efficacy and tolerability of neoadjuvant chemotherapy (Rescue M-VEC) and preoperative radiation therapy for infiltrating bladder cancer: results of an 18-month follow-up.
    Voce S, Montanari F, Arnone S, Dal Pozzo C, Suprani G, Cerullo G, Fornarola V.
    Arch Esp Urol; 1992 Jun 01; 45(5):491-8. PubMed ID: 1510485
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The current status of perioperative chemotherapy for invasive bladder cancer: a multiinstitutional retrospective study in Japan.
    Matsui Y, Nishiyama H, Watanabe J, Teramukai S, Ono Y, Ohshima S, Fujimoto K, Hirao Y, Fukushima M, Ogawa O.
    Int J Clin Oncol; 2005 Apr 01; 10(2):133-8. PubMed ID: 15864700
    [Abstract] [Full Text] [Related]

  • 17. Neoadjuvant treatment of cancer of the bladder with M-VAC/M-VEC, and bladder-sparing policy: preliminary report of a non-randomized study.
    Galante E, Ferroni C, Bianchi S, Megale C, Molinaro S, Maymone S.
    J Exp Ther Oncol; 1996 Jul 01; 1(4):237-41. PubMed ID: 9414410
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Adjuvant methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma.
    Soga N, Arima K, Sugimura Y.
    Int J Urol; 2008 Sep 01; 15(9):800-3. PubMed ID: 18651862
    [Abstract] [Full Text] [Related]

  • 20. Prognostic significance of adjuvant cisplatin-based combination chemotherapy following radical cystectomy in patients with invasive bladder cancer.
    Muramaki M, Miyake H, Kurahashi T, Takenaka A, Inoue TA, Fujisawa M.
    Int J Urol; 2008 Apr 01; 15(4):314-8. PubMed ID: 18380818
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.